Startseite
Kongressberichte 2021
ESMO Congress 2021
Saturday, September 18
Mini oral sessions
Non-metastatic NSCLC and other thoracic malignancies
Non-metastatic NSCLC and other thoracic malignancies
1151MO
Pathological response is an independent factor of overall survival and disease-free survival after neoadjuvant durvalumab in resectable non-small cell lung cancer (NSCLC) in the IFCT-1601 IONESCO phase 2 trial.
Wisle, et al.
Conclusions
The IFCT-1601 IONESCO trial showed for the first time that the extent of pathological response to a neoadjuvant immune checkpoint inhibitor is an independent prognostic factor of OS and DFS in NSCLC.
1732MO
Pembrolizumab and Nintedanib for Patients with Advanced Mesothelioma
F-X. Danlos, et al.
Conclusions
With a BORR of 23% and a DCR of 47% at 6 months, [P]+[N] combination provided valuable therapeutic benefits for Pts with aMM. Flow cytometry and secretome on fresh baseline tumor biopsies are simple techniques which could be used to predict treatment efficacy in aMM Pts.
LBA43
GEMSTONE-301: A randomized, double-blind, placebo-controlled, phase 3 study of sugemalimab in patients with unresectable stage III non-small cell lung cancer (NSCLC) who had not progressed after concurrent or sequential chemoradiotherapy (CRT)
Y-L. Wu, et al.
Conclusions
A statistically significant and clinically meaningful improvement in PFS was observed with sugemalimab vs placebo, with a well-tolerated safety profile. These results provide evidence for sugemalimab as a consolidation treatment for pts with unresectable stage IIIA–C NSCLC who have not progressed following cCRT or sCRT.
1171MO
PACIFIC-R Real-World Study: Treatment Duration and Interim Analysis of Progression-Free Survival in Unresectable Stage III NSCLC Patients Treated with Durvalumab After Chemoradiotherapy
Girard, et al.
Conclusions
These results demonstrate the effectiveness of consolidation durvalumab after CRT in a real-world cohort of pts with unresectable Stage III NSCLC; pneumonitis events were mostly moderate in severity. Additional data from an externally sponsored study with similar enrolment criteria in Spain will be included in the final presentation.
LBA61
Durvalumab _ tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): 3-year overall survival update from the Phase 3 CASPIAN study
Paz-Ares, et al.
Conclusions
D + EP demonstrated sustained OS benefit over EP with a well-tolerated safety profile after >3 years of median follow-up, consistent with previous analyses. 3 times more pts were estimated to be alive at 3 years when treated with D + EP vs EP alone, further establishing D + EP as standard of care for first-line treatment of ES-SCLC.
1172MO
Durvalumab consolidation in patients with stage III non-resecable NSCLC with driver genomic alterations
Riudavets Melia, et al.
Conclusions
We observed limited activity of durvalumab consolidation in pts with stage III non-resecable NSCLC with dGA, except for those harbouring KRASm. Larger studies are needed to confirm these findings.